Synthetic Biologics to Present at the Biotech Showcase™ 2014 Conference

ROCKVILLE, Md., Jan. 8, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the Biotech Showcase™ 2014 conference next week in San Francisco, as follows:

Date: Wednesday, January 15, 2014
Time: 9:30 a.m. (PT)/12:30 p.m. (ET)
Location: Room-Mission II, Parc 55 Wyndham San Francisco Union Square Hotel

(Logo: https://photos.prnewswire.com/prnh/20130522/MM19465LOGO)

A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the internet at http://www.media-server.com/m/p/5hizpa44. After the presentation, a replay will be archived and accessible for 30 days at the same website.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of product candidates for serious infectious and other diseases. Synthetic Biologics is developing oral treatments targeting archaea, a non-bacterial intestinal form of life increasingly associated with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, a series of monoclonal antibodies (mAbs) for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of IBS. In addition, the Company is developing an oral estriol drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS (with results of an ongoing 164 subject, 15 center, two-year, double blind, placebo controlled, Phase II relapsing-remitting MS clinical trial expected to be announced during the first half of 2014). For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.

SOURCE Synthetic Biologics, Inc.